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OBJECTIVES: Primary (ﬁrst and subsequent cycles) prophylaxis
with colony stimulating factors is recommended in the 2006
ASCO and EORTC clinical guidelines when the risk of febrile
neutropenia (FN) is ≥20%. In clinical practice ﬁlgrastim has
often been used for fewer than the recommended 11 days, which
has been shown to compromise clinical outcomes. This study has
evaluated, from an Italian perspective the cost-effectiveness of
pegﬁlgrastim vs. ﬁlgrastim (11- or 6-days) primary prophylaxis
in breast cancer patients receiving chemotherapy with ≥20% FN
risk. METHODS: We constructed a decision-analytic model
from a payer’s perspective. Direct costs were taken from ofﬁcial
price lists or literature data; they included: drugs, drug adminis-
tration, FN-related hospitalizations and subsequent medical
charges. FN risk (varied by days of ﬁlgrastim), FN case-fatality,
relative dose intensity (RDI) of chemotherapy, its impact on sur-
vival, and utility scores were based on a comprehensive litera-
ture review and expert panel validation. Breast cancer mortality
and all-cause deaths were obtained from ofﬁcial statistics. Model
robustness was tested using multi-way sensitivity analyses.
RESULTS: Pegﬁlgrastim appeared to be more effective and less
expensive than 11- and 6-day ﬁlgrastim. The average cost, risk
of FN (%), life expectancy and quality-adjusted life year (QALY)
per person for pegﬁlgrastim, 11-day ﬁlgrastim, and 6-day ﬁl-
grastim were €3316, 7%, 16.47 years, and 15.32 QALY; €5240,
12.5%, 16.41 years, and 15.27 QALY and €3630, 17.5%, 16.35
years, and 15.22 QALY, respectively. The results were sensitive
to the relative costs of drugs and FN risk. Age and cancer stage
had minimal impact. CONCLUSIONS: These preliminary 
data conﬁrm that primary prophylaxis with pegﬁlgrastim may
improve health outcomes and suggest that, in Italy, it could be
cost-saving when compared with ﬁlgrastim (also for less than 11
days). A larger application of the sensitivity analyses will be nec-
essary to further validate the model.
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OBJECTIVES: To evaluate the sensitivity of the cost per QALY
of trastuzumab for the treatment of EBC using one-way and
probabilistic sensitivity analysis (PSA). METHODS: A 5-state
Markov model with annual transition cycles was constructed to
estimate the long-term health outcomes of EBC patients based
on results from the HERA clinical trial. Population-based utili-
ties were used for the health states in the model. NHS resource
use and costs were estimated from a consensus panel of experts
and published unit costs respectively. Costs and beneﬁts were dis-
counted at 3.5% per annum. Using the base case Markov model,
key assumptions and model parameters were varied through
plausible ranges identiﬁed in the literature to evaluate the sta-
bility of the base case cost per QALY. Key assumptions modiﬁed
in the sensitivity analysis included: 1) proportion of patients
receiving trastuzumab in the metastatic setting in both the Adju-
vant trastuzumab and No adjuvant trastuzumab arms when they
develop metastatic disease; 2) baseline patient age; 3) the dura-
tion of the treatment effect of trastuzumab; 4) the baseline risk
of disease progression. Five thousand iterations were applied in
the PSA with beta pert and beta distributions applied to the
ranges of each parameter. RESULTS: The estimated base case
cost per QALY for adjuvant trastuzumab was low at £2387.
Trastuzumab remained cost effective in all evaluated scenarios
with the cost per QALY always falling below the cost effective-
ness threshold of £30,000. The parameters with the largest
impact upon the cost per QALY were the re-treatment rate in the
metastatic setting and the duration of the treatment effect. 100%
of all iterations were below £30,000 per QALY in the PSA.
CONCLUSION: The cost per QALY of trastuzumab for the
treatment of EBC has been demonstrated to be robust and
remain below commonly accepted thresholds despite wide vari-
ations in model assumptions.
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Deﬁnitive radiotherapy is the current standard of care for
patients with locally advanced squamous cell carcinoma of the
head and neck (SCCHN) who are contraindicated and/or not
able to tolerate the severe acute and late toxicities associated
with concomitant chemoradiotherapy. Erbitux (cetuximab) in
combination with radiotherapy has been shown to signiﬁcantly
improve patient outcomes when compared to radiotherapy alone
without aggravating the side effects of radiotherapy. OBJEC-
TIVE: To estimate the cost-effectiveness of Erbitux in combina-
tion with radiotherapy (ERT) compared to radiotherapy alone
(RT), for the treatment of locally advanced head and neck cancer
in patients for whom chemoradiotherapy is inappropriate or
intolerable in Spain. METHODS: A decision-analytic model 
was used to estimate the clinical and economic consequences 
of locally advanced SCCHN. Model parameters and health
resources use were derived from an international phase III clin-
ical trial. Costs were obtained from local data and validated by
local clinical experts. Effectiveness was measured as progression-
free survival (PFS) and QALYs gained and extrapolated beyond
trial follow-up. Costs and outcomes were discounted at an
annual rate of 3%. RESULTS: ERT was associated with an incre-
mental effectiveness of 1.17 years free of disease progression 
and 0.97 QALYs, and with additional cost per patient of about
€8777 resulting in incremental cost-effectiveness ratios of €7532
per progression-free life years and €9091 per QALY gained. The
probabilistic sensitivity analysis showed that the probability of
ERT being cost-effective at the accepted cost-effectiveness thresh-
old in Spain of €30,000 per QALY is over 99%. CONCLU-
SIONS: Cetuximab added to radiotherapy is a cost-effective
option compared to radiotherapy alone, with better outcomes at
a reasonable additional cost. Its clinical and pharmacoeconomic
proﬁle makes Cetuximab + radiotherapy the optimal treatment
for a signiﬁcant proportion of patients with locally advanced
SSCHN who are unable to tolerate or are contra-indicated to
Chemo-Radiotherapy.
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OBJECTIVE: A comprehensive decision model has been devel-
oped and adopted to the Hungarian health care settings to eval-
uate the cost-effectiveness of letrozole as adjuvant therapy for
breast cancer compared to tamoxifen. METHODS: The analy-
